Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRevention of Macular EDema After Cataract Surgery

Trial Profile

PRevention of Macular EDema After Cataract Surgery

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Bromfenac (Primary) ; Dexamethasone (Primary) ; Triamcinolone (Primary)
  • Indications Diabetic macular oedema; Retinal oedema
  • Focus Therapeutic Use
  • Acronyms PREMED
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 13 Apr 2017 Status changed from recruiting to completed.
    • 06 Apr 2017 The trial has been completed in Germany, according to European Clinical Trials Database (End date: 13 Jan 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top